Shionogi has patented a pharmaceutical composition for treating chronic cough with minimal taste disturbance. The method involves administering a specific compound. GlobalData’s report on Shionogi gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Shionogi & Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Shionogi, Cancer treatment biomarkers was a key innovation area identified from patents. Shionogi's grant share as of January 2024 was 54%. Grant share is based on the ratio of number of grants to total number of patents.

Pharmaceutical composition for treating chronic cough

Source: United States Patent and Trademark Office (USPTO). Credit: Shionogi & Co Ltd

A recently granted patent (Publication Number: US11883407B2) discloses a method for treating chronic cough by administering a compound represented by Formula (I). The method aims to address refractory chronic cough and ensures that the compound or its pharmaceutically acceptable salt has minimal side effects related to taste disturbance. The treatment involves administering the compound once daily, with a recommended daily dose ranging from 50 mg to 300 mg, tailored to the individual's needs.

Furthermore, the method provides flexibility in dosing, allowing for variations in the daily dose between 50 mg to 150 mg or 150 mg to 300 mg, depending on the patient's condition. The administration of the treatment can be optimized by taking it once daily after a meal or at bedtime. Additionally, the method specifies different types of cough, such as 24-hour cough or daytime cough, indicating the versatility of the treatment in addressing various forms of chronic cough. Overall, this patented method offers a targeted approach to managing chronic cough effectively while minimizing potential side effects, providing a promising solution for individuals suffering from this condition.

To know more about GlobalData’s detailed insights on Shionogi, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies